

1. Record Nr.	UNINA9910831047903321
Titolo	From genome to therapy : integrating new technologies with drug development
Pubbl/distr/stampa	[Place of publication not identified], : John Wiley, 2000
ISBN	1-280-55549-1 9786610555499 0-470-85183-X 0-470-84664-X
Edizione	[1st ed.]
Descrizione fisica	1 online resource (173 pages)
Collana	Novartis Foundation symposium From genome to therapy
Disciplina	615/.19
Soggetti	Pharmacogenomics Pharmacogenetics Pharmacology Computational Biology Drug Discovery Genetics Investigative Techniques Biology Biological Science Disciplines Health Occupations Chemistry, Pharmaceutical Natural Science Disciplines Disciplines and Occupations Chemistry Analytical, Diagnostic and Therapeutic Techniques and Equipment Drug Design Genomics Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph

Sommario/riassunto

This important and exciting work brings together a high-calibre group of experts to discuss the practical application of genomic information to the development of drugs. Recent technological advances have led to a rapid acceleration in our ability to gather genetic data. The complete genetic sequences are now known for several organisms and accelerated programmes are in place for sequencing many other genomes, including human. The speed with which complete sequencing can be accomplished will continue to increase as new technologies come online. In principle, the scope for developing new diagnostic techniques and drugs is now greater than at any time in human history, but the pathway from genetic information to usable drug is a long and complex one. This major book covers such subjects as the current state of the art in sequencing technology, the applications of these new technologies to sequencing the genomes of various organisms, and the challenge of proteomics. Additional contributions deal with legal and ethical implications of the new uses of genetic data, and functional genomics from the point of view of the pharmaceutical industry.
